Cytokinetics
Clinical trials sponsored by Cytokinetics, explained in plain language.
-
New heart drug aficamten challenges standard Beta-Blocker in major trial
Disease control CompletedThis study tested a new drug called aficamten against the standard medicine metoprolol in 175 adults with a heart condition that makes the heart muscle thick and blocks blood flow. The goal was to see which drug better improves exercise ability and symptoms like shortness of brea…
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill aims to help heart patients breathe easier and move more
Disease control CompletedThis Phase 3 trial tested a daily pill called aficamten in 282 adults with a type of thickened heart muscle that blocks blood flow and causes symptoms like shortness of breath and chest pain. Participants received either aficamten or a placebo for 24 weeks. The main goal was to s…
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New heart pill aims to ease thick heart muscle symptoms
Disease control CompletedThis study tested a new daily pill called CK-3773274 (aficamten) in 96 adults with symptomatic hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal was to find the right dose and check safety, including effects on heart pumping strength. P…
Phase: PHASE2 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC